Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
30.03
+1.49 (5.22%)
At close: Mar 19, 2026, 4:00 PM EDT
30.48
+0.45 (1.50%)
After-hours: Mar 19, 2026, 7:30 PM EDT
Celldex Therapeutics Employees
Celldex Therapeutics had 198 employees as of December 31, 2025. The number of employees increased by 12 or 6.45% compared to the previous year.
Employees
198
Change (1Y)
12
Growth (1Y)
6.45%
Revenue / Employee
$7,803
Profits / Employee
-$1,306,854
Market Cap
2.00B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 198 | 12 | 6.45% | 198 | 0 |
| Dec 31, 2024 | 186 | 26 | 16.25% | 186 | 0 |
| Dec 31, 2023 | 160 | 12 | 8.11% | 160 | 0 |
| Dec 31, 2022 | 148 | 14 | 10.45% | 148 | 0 |
| Dec 31, 2021 | 134 | 9 | 7.20% | 132 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Ultragenyx Pharmaceutical | 1,371 |
| Adaptive Biotechnologies | 624 |
| Syndax Pharmaceuticals | 298 |
| Stoke Therapeutics | 128 |
| Aurinia Pharmaceuticals | 128 |
| Tyra Biosciences | 87 |
| Oruka Therapeutics | 68 |
CLDX News
- 20 days ago - Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026 - GlobeNewsWire
- 22 days ago - Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 22 days ago - Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria - GlobeNewsWire
- 24 days ago - Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab's First-in-Class and Best-in-Disease Profile - GlobeNewsWire
- 5 weeks ago - Celldex to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - MoneyShow's Best Investment Ideas For 2026: Part 3 - Seeking Alpha
- 3 months ago - Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism - GlobeNewsWire
- 4 months ago - Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer - GlobeNewsWire